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Summary
The syndrome of apparent mineralocorticoid excess
(AME) is a heritable form of hypertension in which cor-
tisol acts as a potent mineralocorticoid. The type I var-
iant results in a severe clinical and biochemical pheno-
type and arises because of mutations in the gene
encoding the type 2 isozyme of 11b-hydroxysteroid de-
hydrogenase (11b-HSD2), an enzyme responsible for the
peripheral inactivation of cortisol to cortisone. Only
mild abnormalities of cortisol metabolism have been
found in the type II variant of AME, suggesting that it
may be a separate gene defect. In an extensive consan-
guineous Sardinian pedigree affected with “type II”
AME, a novel homozygous point mutation (C945T) was
found in the human 11b-HSD2 gene in four affected
individuals. Thirteen family members were heterozygous
for the resultant R279C amino acid substitution. The
LOD score of linkage of the mutation to the disease was
3.23. Expression of the 11b-HSD2 mutant cDNA re-
sulted in an enzyme with reduced maximum velocity,
but similar substrate affinity, compared with activity of
the wild-type cDNA. Affected individuals were 130
years of age and had both mineralocorticoid hyperten-
sion and evidence of impaired metabolism of cortisol to
cortisone. The heterozygote state was phenotypically
normal but was associated with subtle defects in cortisol
metabolism. AME represents a spectrum of mineralo-
corticoid hypertension with severity reflecting the un-
derlying genetic defect in the 11b-HSD2 gene; clas-
sification into distinct subtypes is inappropriate. Hy-
pertensive populations should be screened to identify the
prevalence of milder defects in 11b-HSD2 in patients
currently labeled as having “essential” hypertension.
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Introduction
The syndrome of apparent mineralocorticoid excess
(AME) is a heritable form of hypertension characterized
by hypokalemia with suppression of plasma renin and
aldosterone concentrations (Shackleton and Stewart
1990; White et al. 1997). The condition is associated
with a defect in the peripheral metabolism of cortisol to
hormonally inactive cortisone (Ulick et al. 1979), which
is due to a defect in the activity of the type 2 isozyme
of 11b-hydroxysteroid dehydrogenase (11b-HSD2).
This defect in cortisol metabolism results in an increased
plasma cortisol half-life; but patients are not Cushin-
goid, because a concomitant fall in cortisol production
rate ensures normal circulating levels. The causativemin-
eralocorticoid in AME is cortisol itself (Oberfield et al.
1983; Dimartino-Nardi et al. 1987; Stewart et al. 1988);
failure of inactivation of cortisol by 11b-HSD2 results
in cortisol instead of aldosterone binding to the min-
eralocorticoid receptor in kidney and colon.
Two types of AME have been reported. Type I AME
is characterized by a marked increase in the ratio of
urinary excretion of A-ring–reduced cortisol metabolites
(tetrahydrocortisol [THF]allo-THF) to cortisone me-
tabolites (tetrahydrocortisone [THE]) (Shackleton et al.
1985; Monder et al. 1986) and arises because of mu-
tations in the 11b-HSD2 gene (Mune et al. 1995; Wilson
et al. 1995a, 1995b; Stewart et al. 1996; White et al.
1997). In contrast, although the type II variant of AME
results in a similar hypertensive phenotype (Tedde et al.
1992), the urinary THFallo-THF/THE ratio is rela-
tively normal (Ulick et al. 1990; Mantero et al. 1994),
leading some investigators to suggest that it may rep-
resent a separate gene defect (Ulick et al. 1992). We
report the clinical features, biochemical studies, and mo-
lecular basis for hypertension in an extended Sardinian
pedigree with AME type II.
Subjects and Methods
Clinical Summary
The extended pedigree had 37 subjects in five gener-
ations, 23 of whom were available for evaluation (fig.
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Figure 1 Family tree of a Sardinian kindred with AME. Haplotypes for the R279C mutation in the human 11b-HSD2 gene are shown
as homozygous affected individuals (blackened symbols), heterozygous individuals (half-blackened symbols), or homozygous normal controls
(unblackened symbols containing “N”; unblackened symbols that do not contain an “N” denote individuals who were not available for study).
1). Clinical details on patients 14–16 have been reported
elsewhere (Ulick et al. 1990, 1992; Tedde et al. 1992;
Mantero et al. 1994). In brief, patient 14 is a 36-year-
old woman who presented, at age 27 years, with hy-
pertension (blood pressure [BP] 160/100 mmHg) and
borderline hypokalemia (3.2–3.5 mmol/liter). Her uri-
nary THFallo-THF/THE ratio was initially reported
to be moderately elevated, at 2.56 (reference range
0.6–1.5). Patients 15 and 16 are siblings. Patient 15 pre-
sented, at age 10 years, with paralytic ileus and was
found to be hypertensive (BP 240/110 mmHg) and hy-
pokalemic (1.8–2.8 mmol/liter). A younger sister (pa-
tient 16) also was found to be severely hypertensive, at
age 10 years (BP 240/110 mmHg) and to have hypo-
kalemia (2.1 mmol/liter). Both patient 15 and patient
16 complained of fatigue, polyuria, and polydipsia and
had growth retardation, nephrocalcinosis, and rickets.
The THFallo-THF/THE ratio initially was reported to
be 1.41 and 1.26, respectively, in these two individuals.
Patient 13 is the sister of patient 14. She is a 32-year-
old woman who presented, at age 27 years, with hy-
pertension during the third trimester of her second preg-
nancy. BP prior to this and, specifically, during her first
pregnancy, 2 years earlier, had been reported to be nor-
mal, although she had suffered from a single episode of
renal colic at age 24 years. During her pregnancy and
after delivery, her BP was controlled with nifedipine in
doses of 20 mg twice a day. As with patients 14–16
(Tedde et al. 1992; Mantero et al. 1996), dexamethasone
in doses of 0.5 mg twice a day was shown to induce a
natriuresis and to elevate plasma potassium concentra-
tions (data not shown). When studied while she was off
all therapy for 6 mo postpartum, her BP was 150/110
mmHg, her potassium was 2.9 mmol/liter, and her uri-
nary THFallo-THF/THE ratio was 1.44.
A more detailed and extensive biochemical and clin-
ical characterization of the kindred recently has been
completed, and the results are depicted in table 1. Pa-
tients 13–17 had therapy withdrawn for 14 d, and all
subjects were evaluated on the basis of an ad lib sodium
intake. Systolic and diastolic BP were recorded as the
mean of three clinical BP readings. Supine plasma renin
activity (PRA) was measured by radioimmunoassay
(RENCTK; Sorin Biomedica). Normal reference values
are 0.5–5 ng angiotensin I/ml/h. A 24-h urine collection
was taken and analyzed for cortisol metabolites, by gas
chromatography/mass spectrometry (GC/MS), and for
urinary aldosterone (ALDOCTK; Sorin Biomedica) (ref-
erence range 5–25 mg/24 h).
Urinary Steroid Analysis
The total urinary steroid profile (conjugated and free
steroids) was determined by GC/MS using a Hewlett-
Packard 5970 instrument as reported elsewhere (Shack-
leton 1993). THE, THF, and allo-THF are included
within this profile. GC/MS also was used for measure-
ment of urinary free cortisol (UFF) and urinary free cor-
tisone (UFE), by a different but recently published
method employing stable isotope-labeled internal stan-
dards (Palermo et al. 1996).
Genotypic Studies
DNA was obtained from 23 members of the Sardinian
family, from peripheral blood leukocytes (DNA extrac-
tion kit; Nucleon Biosciences). In every case, direct se-
quencing of the entire 11b-HSD2 gene by exon-specific
PCR amplification was undertaken as reported else-
where (Stewart et al. 1996). The PCRmixture contained
50 ng of genomic DNA, 10 mM of each dNTP, reaction
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Table 1
Clinical, Biochemical, and Genetic Data for Individuals Depicted in Figure 1
Patient (Sex/
Age [years]) Genotype
THFallo
THF/THE
Ratio
UFF/UFE
Ratio
BP
(Systolic/Diastolic)
Plasma
Potassium
(mmol/liter)
PRA
(ng/ml/h)
Urinary
Aldosterone
Excretion
(mg/24 h)
13 (F/32) Homozygous R279C 1.9 7.5 150/110 2.9 1.72 .05
14 (F/36) Homozygous R279C 4.26 1.45 160/100 2.6 .76 .05
15 (M/33) Homozygous R279C 4.53 3 180/140 1.8 .002 .05
16(F/32) Homozygous R279C 3.19 5.5 175/135 2.1 .046 .05
9 (M/54) Heterozygous R279C 1.29 .37 156/108 5.3 9.09 2.37
10 (F/47) Heterozygous R279C .8 .7 154/96 4.8 1.12 3.52
11 (F/58) Heterozygous R279C 1.7 .8 166/90 4.2 .54 1.22
12 (M/68) Heterozygous R279C 1.2 .75 160/100 4.0 4.27 4.29
17 (M/29) Heterozygous R279C 1.17 1.0 186/98 4.5 3.03 3.5
19 (F/17) Heterozygous R279C 1.0 .5 128/80 4.5 3.28 27.1
20 (M/25) Heterozygous R279C .85 .63 138/88 4.6 6.88 5.94
22 (F/11) Heterozygous R279C .57 .56 104/64 4.7 1.11 1.4
23 (M/15) Heterozygous R279C .45 .76 128/80 4.3 4.61 3.3
27 (M/8) Heterozygous R279C .65 1.19 90/60 4.3 3.23 7.64
28 (F/4) Heterozygous R279C .5 1.72 80/60 4.5 3.1 11.33
29 (F/18) Heterozygous R279C .65 .96 120/70 4.5 4.39 2.37
30 (M/35) Heterozygous R279C 130/70 4.2 2.64 2.31
6 (F/87) Normal 136/80 3.8 1.58 2.69
21 (M/14) Normal .4 .28 110/70 4.4 2.52 1.79
24 (M/20) Normal .75 .65 152/90 4.5 3.91 7.96
25 (F/22) Normal .82 .48 110/74 4.4 2.55 1.64
26 (M/30) Normal 120/70 4.1 .83
31 (M/38) Normal 115/70 3.9 4.15 4.02
buffer (10 mM Tris-HCl, 1.5 mM MgCl2, and 50 mM
KCl; pH 8.3), 1 unit of Taq DNA polymerase (Boehrin-
ger Mannheim), and 20 pmol of each primer, in a final
reaction volume of 50 ml. Specifically, for the described
mutation in exon 5, the primers were 5′-CAG TCC TAA
TTG GCT TTG GC and 3′-GTG ATG GCA TCT ACA
ACT GG; the PCR program was 35 cycles of 94C for
20 s, 56C for 30 s, and 72C for 1 min. Purified PCR
products were sequenced by the direct chain-termination
sequencing method with fluorescent-tagged dideoxynu-
cleotides analyzed on an automatic DNA sequencer (Ap-
plied Biosystems).
To further validate the sequencing results, 1 mg of
DNA obtained from PCR amplification of exon 5 was
digested with 5 units of HhaI (Promega) in a 20-ml vol-
ume, by use of Promega Restriction Enzyme Buffer C
(10 mM Tris-HCl, 10 mM MgCl2, and 50 mM NaCl)
for 1 h at 37C. The digested products were electro-
phoresed in 3% agarose gels.
Expression Studies
Site-directed mutagenesis.—Full-length 11bHSD2
cDNA was subcloned into pALTER vector (Promega)
and was mutagenized as described elsewhere (Obeye-
sekere et al. 1995). The synthetic oligonucleotide—5′-
TCA GTG GGA AAA GTG CAA GCA ATT GCT-3′
(corresponding to nucleotides 932–958) was used to
construct the R279C mutant (C945T). The mutation
was confirmed by DNA sequencing of the corresponding
coding region, by means of the Sequenase 2 sequencing
kit (United States Biochemical). Mutated cDNA was re-
cloned into the mammalian expression plasmid pcDNA1
(Invitrogen) and was transfected into mammalian Chi-
nese hamster–ovary polyoma (CHOP) cells as described
elsewhere (Albiston et al. 1994).
Analysis of enzyme activity in homogenates.—Forty-
eight hours after transfection, CHOP cells were washed
and harvested into homogenizing buffer (0.25M sucrose
and 10 mM sodium phosphate; pH 7.4), were sonicated
briefly, and then were stored at70C prior to use. 11b-
HSD2 activity in homogenates was determined by mea-
surement of the conversion of [3H]-cortisol to cortisone,
in the presence of cofactor. Specifically, the determina-
tion of 11b-HSD2 enzyme kinetics for cortisol was per-
formed by incubation of 100 mg of transfected CHOP-
cell homogenates at 37C for 60 min, with substrate
concentrations of 2 nM [3H]-cortisol and 25–800 nM
of unlabeled cortisol, in the presence of 500 mM NAD.
Incubations were performed at 37C in a total volume
of 500 ml of assay buffer (50 mM Tris-HCl, 2 mM
EDTA, 1 mM MgCl2, 1 mM DTT, 20% glycerol, and
500 mM NAD; pH 7.4). The reaction was terminated
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by the addition of 3 vol of ethyl acetate, steroids were
extracted and were separated by thin-layer chromatog-
raphy, and the fractional conversion of cortisol to cor-
tisone was calculated. The transfection experiments for
both wild-type and mutant 11b-HSD2 cDNAs were per-
formed on three separate occasions, and each experi-
ment was done in triplicate.
Western blot analysis.—CHOP-cell homogenate pro-
teins (50 mg) from wild-type and R279C mutant 11b-
HSD2 were separated by 5%–15% gradient SDS-PAGE
under reducing conditions and were transferred to ni-
trocellulose filters (Scheicher and Schuell), for 2 h, on
ice. After nonspecific sites were blocked on nitrocellu-
lose, the blot was incubated overnight at 4C with sheep
anti-HSD2 polyclonal antibody (Shimojo et al. 1997)
diluted to 1/1,000 with 0.5% skim milk powder in PBS
pH 7.4 and 0.1% Tween 20. After incubation at room
temperature for 60 min with the second anti-rabbit IgG
labeled with peroxidase at a dilution of 1/1,000, the
blots were washed in PBS/0.1%Tween 20–60min before
revelation by a chemiluminescence-detection kit (Du-
Pont NEN) used according to the manufacturer’s in-
structions. This was done for each of the transfection
experiments, and the immunoblots were quantified by
densitometry.
Statistical analysis.—Where appropriate, results were
expressed as mean  standard error (mean SE), and
statistical analysis was undertaken by means of an un-
paired t-test.
Results
The extended Sardinian pedigree is depicted in fig-
ure 1.
Genotypic Studies
Sequence analysis of the 11b-HSD2 gene revealed a
point mutation, C945T in exon 5 of the 11b-HSD2 gene,
resulting in an amino acid substitution of arginine by
cysteine at codon 279 of the enzyme protein (R279C).
No other mutation was found in the coding or promoter
region of the 11b-HSD2 gene. This mutation results in
the loss of an HhaI restriction site (GCG CGT GC) in
exon 5;HhaI restriction polymorphism was used to con-
firm the genotype of the C945Tmutation in the pedigree.
Patients 13–16 were homozygous for the R279C mu-
tation, as detected by direct sequencing (fig. 2) and con-
firmed by HhaI restriction-site polymorphism (fig. 3).
Other family members were either heterozygous for the
R279Cmutation ( [including patient 17, who hadn  13
mild hypertension]) or homozygous normal ( ), inn  6
keeping with an autosomal recessive mode of inheritance
(tables 1 and 2). A LOD score of linkage of the R279C
mutation to the disease, applied to the kindred, gave a
value of 3.23 (i.e., odds for linkage 11,000:1).
Coincidentally, several differences (nucleotide substi-
tutions at codons 451 TrG, 453 TrG, 1162 GrC, and
1210 GrC and a G insertion at codon 790) were noted
with comparison of the published data for the 11b-
HSD2 genomic DNA sequence deposited in GenBank.
With the exception of amino acid substitution L148V
in exon 2, none of these altered the coding region. These
differences have been confirmed by sequencing of ad-
ditional Caucasian and Afro-Caribbean controls (n 
in each group) and represent errors in the sequence50
submitted to GenBank.
Clinical and Biochemical Data
As shown in tables 1 and 2, when compared with
other family members, patients 13–16 had significant
suppression of the renin-aldosterone axis, reduced
plasma potassium levels, and elevated BP, in keeping
with a mineralocorticoid-excess state. Urinary steroid
profiles showed a significant elevation of the THFallo-
THF/THE ratio and UFF/UFE ratio in homozygous af-
fected patients, compared with both homozygous nor-
mal controls and heterozygotes; however, in affected
patients the UFF/UFE ratio was more abnormal than the
THFallo-THF/THE ratio, and it was significantly
higher in heterozygotes than in normal controls (P !
). In BP, plasma potassium, PRA, and urinary aldo-.05
sterone, there were no significant differences between the
heterozygotes and the normal controls. Three hetero-
zygotes (patients 9, 12, and 17) had BP values consis-
tently 1160/95 mmHg, but none had evidence of min-
eralocorticoid excess and all had normal PRAs and
aldosterone levels, suggesting an alternative cause of
their hypertension. Patient 17 is a 29-year-old man with
a 2-year history of hypertension, and, although his PRA
and urinary aldosterone and potassium levels were nor-
mal, his UFF/UFE ratio was 1.0. Two other heterozy-
gotes (patients 27 and 28) had a UFF/UFE ratio 11, but
without evidence of hypertension or mineralocorticoid
excess.
The allo-THF/THF ratio was normal in the homo-
zygous affected patients. In comparison, in 10 patients
with the so-called type 1 AME who, during the recent
past, had been studied in our laboratory (C.H.L.S.), the
THFallo-THF/THE ratio was 12–70 and the UFF/UFE
ratio was 8–25. The allo-THF/THF ratio was elevated,
at (mean  SE; ).3.1 0.7 n  10
Expression Studies
Conversion of cortisol to cortisone in untransfected
CHOP cells was always !2%. Lineweaver-Burke plots
indicated that the R279C mutant enzyme had the same
affinity for F as did the wild-type enzyme (K m
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Figure 2 Automated sequence analysis of genomic DNA from part of exon 5 of the human 11b-HSD2 gene, showing homozygosity for
the wild type, in a normal control (patient 26), homozygosity for the C945T mutation, in an affected individual ( patient 14), and heterozygosity,
in the mother (patient 11) of an affected individual.
Figure 3 HhaI restriction-site polymorphism of exon 5 of the
11b-HSD2 gene. The expected PCR product is 239 bp, and HhaI
digestion reveals two products of expected size, 141 bp and 98 bp.
The C945T mutation results in a loss of theHhaI restriction site. Lanes
1 and 5, DNA molecular-weight marker VIII. Lane 2, Affected patient
(homozygous for C945T), demonstrating only the undigested PCR
product. Lane 3, Affected patient’s mother (heterozygous), demon-
strating three bands; Lane 4, Normal control (wild-type homozygous),
demonstrating two bands with complete digestion.
); however, there was a difference in the maximal54 nM
rate of reaction, with a decrease in maximum oxygen
consumption (Vmax), from pmol cortisone/mg/7.3 0.9
min, for the wild-type enzyme, to pmol/mg/4.8 1.3
min, for the R279C mutant enzyme ( , in triplicate;n  3
) (fig. 4a and b). This could not be explained onP ! .05
the basis of transfection efficiency, in that similar levels
of wild-type and R279Cmutant 11b-HSD2 proteinwere
expressed in each transfection experiment (fig. 4c); when
quantified by densitometry, these levels were 5.3 and 5.7
arbitrary units, respectively ( ).n  3
Discussion
The syndrome of AME was characterized first during
the late 1970s, by Ulick and New (Ulick et al. 1979),
although, in retrospect, it can be seen that the first case
was reported in 1974 (Werder et al. 1974). Since then,
∼50 cases have been reported worldwide (Shimojo and
Stewart 1995; White et al. 1997). Patients usually pre-
sent in childhood, with severe hypertension, life-threat-
ening hypokalemia, and suppression of the renin-angi-
otensin-aldosterone system. AME is associated with
abnormalities in the peripheral metabolism of corti-
sol—specifically, an increase in the excretion of the “A-
ring”–reduced cortisol metabolites (i.e., THF and allo-
THF) to those of cortisone (i.e., THE), suggesting de-
fective 11b-HSD activity. Other defects in cortisol me-
tabolism in AME also have been observed, including
defective 5b-reductase activity (manifested as an increase
in the allo-THF/THF ratio) (Ulick et al. 1979; Oberfield
et al. 1983; Shackleton et al. 1985; Monder et al. 1986;
Stewart et al. 1988). After an extensive search for the
underlying mineralocorticoid, it eventually was estab-
lished that cortisol itself is the offending mineralocor-
ticoid in AME (Oberfield et al. 1983; Dimartino-Nardi
et al. 1987; Stewart et al. 1988). Through these clinical
studies, a vital role for 11b-HSDwas uncovered. In vitro,
Li et al.: Type II AME 375
Table 2
Systolic and Diastolic BP, Plasma Potassium, PRA, Urinary Aldosterone Excretion,
and Cortisol/Cortisone Metabolites in a Sardinian Kindred with AME Type II
MEAN  SE IN
Homozygotes
( )n  4
Heterozygotes
( )n  13
Normal Controls
( )n  6
BP (mmHg):
Systolic 166.3  7.9* 133.8  8.5 123.8  6.9
Diastolic 121.3  9.6* 81.8  4.5 75.7  3.3
Plasma potassium (mmol/liter) 2.3  .2* 4.5  .1 4.2  .1
PRA (ng/ml/h) .63  .4* 2.59  .53 3.64  .65
Urinary aldosterone (mg/24 h) .05  0* 3.6  1.2 5.9  1.9
THFallo-THF/THE ratio 3.4  .6* .90  .11 .66  .23a
allo-THF/THF ratio 1.02  .31 1.07  .14 .96  .17a
UFF/UFE ratio 4.36  1.34* .83  .10** .47  .13a
a A urinary steroid profile was available for only three normal controls.
* or versus normal controls and heterozygotes.P ! .05 P ! .01
** versus normal controls.P ! .05
the mineralocorticoid receptor (MR) has similar intrinsic
affinity for cortisol and aldosterone (Krozowski and
Funder 1983; Arriza et al. 1987). In normal physiology,
renal 11b-HSD “shuttles” the much higher relative con-
centrations of cortisol to inactive cortisone, thereby en-
abling aldosterone to bind to the MR (Edwards et al.
1988; Funder et al. 1988). Failure of this “protective”
mechanism in AME results in cortisol acting as a potent
mineralocorticoid (Stewart et al. 1988).
Two isoforms of 11b-HSD have been cloned and char-
acterized in human tissues (Tannin et al. 1991; Albiston
et al. 1994; Stewart et al. 1994a). 11b-HSD1 is pre-
dominantly an NADPH-dependent oxo-reductase found
principally in liver, gonads, decidua, and the CNS. No
mutations in the gene encoding human 11b-HSD1 have
been found in patients with AME (Nikkila¨ et al. 1993).
In contrast, 11b-HSD2 is a high-affinity, NAD-depen-
dent dehydrogenase expressed in high amounts in fetal
tissues (Stewart et al. 1994b) and in the “mineralocor-
ticoid-target” tissues—kidney and colon (Albiston et al.
1994; Whorwood et al. 1995). It is this isoform that, in
an autocrine fashion, protects theMR from cortisol, and
mutations in the gene encoding human 11b-HSD2 have
been reported in patients with AME (Mune et al. 1995;
Wilson et al. 1995b; Stewart et al. 1996). Expression of
the 11b-HSD2 mutant cDNAs results in proteins that
have either severely attenuated or absent enzyme activity,
with a close correlation between genotype and biochem-
ical phenotype (Wilson et al. 1995a; Ferrari et al. 1996;
Mune and White 1996). The condition occurs as an
autosomal recessive trait, establishing AME, alongside
glucocorticoid-remediable hyperaldosteronism and Lid-
dle syndrome, as a cause of hypertension arising from
a single mutation (Gordon 1995).
In 1990, the so-called type II variant of AME was
described in three members of the kindred that we stud-
ied and in an additional two individuals from mainland
Italy (Ulick et al. 1990). These patients differed from
earlier AME patients (type I AME), in that they were
reported to have relatively normal urinary THFallo-
THF/THE ratios; otherwise, their clinical features were
very similar, with evidence of cortisol-induced mineral-
ocorticoid hypertension. The main abnormality in cor-
tisol metabolism was reported to be a generalized defect
in cortisol A-ring metabolism (decreased THFallo-
THF/F ratio) (Ulick et al. 1992; Mantero et al. 1994),
suggesting a defect other than 11b-HSD deficiency. We
recently have suggested that this probably was not the
case (Mantero et al. 1996). First, patients with type I
AME have the same decrease in this “cortisol A-ring
quotient” as is seen in those with AME type II (Shack-
leton et al. 1985; Monder et al. 1986). Second, patients
were shown to have (a) a prolonged plasma half-life for
[11a-3H]-cortisol (Mantero et al. 1994) and (b) an in-
crease in the UFF/UFE ratio (Mantero et al. 1996), both
of which are probably more sensitive markers for the
activity of 11b-HSD2 than is the THFallo-THF/THE
ratio. Finally, as this study has illustrated, the THFallo-
THF/THE ratio, although not grossly elevated, is clearly
not normal in AME type II. On this note, excessive in-
gestion of glycyrrhetinic acid, the active ingredient in
licorice, results in an acquired form of AME, which is
due to inhibition of 11b-HSD2 and which causes an
increase in the urinary THFallo-THF/THE ratio
(1.5–3.0), an increase similar to that seen in so-called
AME type II (Stewart et al. 1987; Farese et al. 1991).
It is clear, therefore, that so-called minor disturbances
in cortisolrcortisone conversion, manifested as slight in-
creases in the THFallo-THF/THE ratio, may result in
a profound clinical phenotype.
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Figure 4 Kinetic analysis of 11b-HSD2 activity in CHOP-cell homogenates transfected with (A) wild-type 11b-HSD2 and (B) R279C-
mutant 11b-HSD2. Km for F was 54 nM in both instances, but Vmax for wild-type 11b-HSD2 was 7.27 pmol cortisone/mg/min, compared with
4.84 pmol/mg/min for R279C-mutant 11b-HSD2. C, Western blot analysis indicating that similar amounts of 11b-HSD2 protein (wild type or
R279C mutant) were expressed in CHOP cells. E  cortisone; and F  cortisol.
This study has found a novel mutation in the human
11b-HSD2 gene in a kindred with AME “type II,” high-
lighting the artificial difference between AME types I
and II. The majority of mutations causing AME are in-
deed ArgrCys, reflecting the observation that the most
common types of point mutations in higher eukaryotes
are CpGrTpG (White et al. 1997). Compared with
other reported cases of AME, the less severe biochemical
and clinical features of the homozygous affected patients
described in this kindred suggest that this mutation
would result in only mild attenuation of enzyme activity,
rather than in absent or severely reduced activity, and
this was confirmed in our expression studies. TheR279C
mutant cDNA encoded an enzyme protein with a normal
Km for cortisol (54 nM) but with a Vmax that was reduced
by 33% of wild-type activity. In the absence of tissue
from affected individuals, our studies employed rigorous
kinetic analyses of mutant 11b-HSD2 activity in cell
homogenates rather than in intact cells. Nevertheless
precedents for mutant enzymes with alterations in Vmax,
rather than with reduced affinity for substrate, have been
reported, notably in some patients with congenital ad-
renal hyperplasia due to homozygous mutations in type
II 3b-HSD (Simard et al. 1995). It is possible that the
R279C mutation results in an alteration in affinity for
NAD or that the amino acid substitution causes a struc-
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tural change in the protein, decreasing its activity, but
further studies are required to explore this. Rather than
divide AME into type I and type II variants, however,
we suggest that this syndrome should be seen as a con-
tinuum, explained on the basis of mutations in the hu-
man 11b-HSD2 gene that have varying degrees of se-
verity. On this note, a preliminary report of a “mild,”
isolated case of AME has been made and has been ex-
plained on the basis of a mutant 11b-HSD2 protein that
has only a slightly reduced affinity (i.e., high Km) for
cortisol (Wilson et al. 1997).
The only persistent difference between our described
kindred and other AME cases was the normal allo-THF/
THF ratio. Coexisting defective 5b-reductase activity
never has been fully explained in AME (Monder et al.
1986). It may relate to secondary changes in activity
that are consequent on the profound changes in 11b-
HSD2 activity. Explaining this in terms of an effect of
cortisol itself, however, would seem to be unconvincing,
because a decrease in the allo-THF/THF ratio (indicative
of defective 5a-reductase activity) is seen in states of
circulating cortisol excess (Phillipou 1982). Further-
more, licorice ingestion, which results in only mild
changes in the THFallo-THF/THE ratio, does increase
the allo-THF/THF ratio (Stewart et al. 1987).
Finally, the identification of milder cases of AME high-
lights the need to address the prevalence of AME and
the role of 11b-HSD2 in patients labeled as having “es-
sential” hypertension. In Sardinia specifically, earlier
data did report an increase in the THFallo-THF/THE
ratio in untreated hypertensives (Soro et al. 1995); the
UFF/UFE ratio was not measured. Our preliminary stud-
ies in normotensive and hypertensive individuals in Sar-
dinia have identified a heterozygote state for the C945T
mutation in ∼1:40 individuals (A. Li, M. Pirastu, M.
Palermo, R. Tedde, and P. M. Stewart, unpublished ob-
servations), suggesting that other homozygous affected
individuals will exist. The relevance of the heterozygote
state remains uncertain. Although the heterozygote state
has been reported to be normal in the majority of cases
of AME (Mune et al. 1995; Stewart et al. 1996), two
hypertensive parents of AME-affected individuals have
been reported (Stewart et al. 1988; Li et al. 1997). These
are of interest because, theoretically, they would possess
an enzyme that has 50% of wild-type activity; and, in-
deed, in both cases, the THFallo-THF/THE ratio was
moderately elevated and similar to values seen our “ho-
mozygous” Sardinian kindred. In this Sardinian kindred,
the heterozygote appeared to be normal. One such in-
dividual (patient 17) was hypertensive, but, in the ab-
sence of evidence of mineralocorticoid excess, it would
be difficult to explain his hypertension as being due to
even a partial defect in 11b-HSD2 activity. Of interest,
however, was the high UFF/UFE ratio in the heterozygote
state, notable in three individuals. Follow-up of these
patients into late adulthood is required for definition of
both the relevance of this abnormality and any subse-
quent development of hypertension.
AME is established as a cause of monogenic hyper-
tension—that is, hypertension resulting from a single-
gene defect. The syndrome reflects a continuum of clin-
ical and biochemical abnormalities of varying severity,
depending on the genotype; classification into distinct
subtypes is inappropriate. The identification of milder
forms of AME emphasizes the need to define its prev-
alence in hypertensive populations.
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